Lexeo Therapeutics Email Format

Biotechnology ResearchNew York, United States51-200 Employees

Lexeo Therapeutics is a clinical-stage biotechnology company focused on developing genetic medicines to address cardiovascular diseases and APOE4-associated Alzheimer's disease. Building on research from Weill Cornell Medicine and the University of California San Diego, the company collaborates with leading institutions to advance its gene therapy programs, using early proof-of-concept data to inform its development pathway. Its work centers on delivering targeted genetic interventions and optimizing manufacturing approaches, with an emphasis on translating scientific advances into potential clinical applications. Based in New York City, Lexeo positions itself within the biomedical research sector, leveraging partnerships and a stepwise development approach to progress its pipeline. The organization operates in a field where advances in gene therapy and precision medicine aim to offer new treatment possibilities for serious, underserved conditions. Recent activity includes participating in major industry conferences and announcements related to its cardiovascular programs and collaborations with other pharmaceutical and biomedical entities.

Get verified Lexeo Therapeutics emails free

Company overview Employee directory